Anzeige
Meldung des Tages: Milliarden aus Washington? Dieser kritische Rohstoff könnte der nächste Profiteur sein

Galderma Group Aktie News

Aktie
WKN:  A407X6 ISIN:  CH1335392721 US-Symbol:  GDERF Branche:  Pharmazeutika Land:  Schweiz
145,70 CHF
+0,00 CHF
0,00%
158,85 € 03.02.26
Depot/Watchlist
Marktkapitalisierung *
41,47 Mrd. €
Streubesitz
16,67%
KGV
103,51
Dividende
0,15 CHF
Dividendenrendite
0,087%
Index-Zuordnung
-
Weiter aufwärts? Long handeln - Jetzt mit Hebel 8,41: MM1L5W
Werbung

Galderma Group News

02.02.26 - Businesswire
Galderma Announces U.S. FDA Acceptance of RelabotulinumtoxinA Biologics License Application Resubmission
Galderma (SIX: GALD) today announced that the U.S. FDA has accepted the BLA resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-​to-severe ...
30.01.26 - Businesswire
Galderma Tackles Menopause-related Skin Changes With Global Survey and Clinical Trial Inclusivity
Galderma (SIX: GALD) has unveiled findings from a global survey of peri- and post-​menopausal women from nine countries exploring the impact of menopause on the skin at the ...
29.01.26 - Businesswire
Galderma Unveils ‘Wake Up To Restylane’, Underscoring Restylane as the Ideal Hyaluronic Acid Treatment for Always-On Natural Beauty
Galderma (SIX: GALD), the pure-play dermatology category leader, has launched ‘Wake Up To Restylane’, a global campaign that showcases Restylane as an everyday beauty ally. ...
22.01.26 - Businesswire
IMCAS 2026: Galderma Showcases the Latest Scientific Advances Behind the Industry’s Broadest Injectable Aesthetics Portfolio
Galderma (SIX: GALD) will present ten posters with the latest updates from across its broad aesthetic portfolio spanning regenerative biostimulation, HA and neuromodulator ...
21.01.26 - Businesswire
Galderma Provides Update on Arbitration Case Regarding Neuromodulator Research and Development Partnership
Galderma (SIX:GALD), the pure-play dermatology category leader, today announced that an International Chamber of Commerce arbitral tribunal issued an award confirming the ...
14.01.26 - Businesswire
TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics
Galderma (SIX: GALD) will present data on its innovative and industry-​leading neuromodulator portfolio at the TOXINS 2026 International Conference in Madrid, Spain from January ...
17.12.25 - Businesswire
New Published Data Confirms Nemluvio® (Nemolizumab) Can Rapidly Relieve Itch and Improve Sleep in as Early as Two Days in Both Atopic Dermatitis and Prurigo Nodularis
Galderma (SIX: GALD), the pure-play dermatology category leader, today released new clinical data confirming nemolizumab’s rapid onset of action on itch and sleep, with significant ...
11.12.25 - Businesswire
Galderma Announces First Patient Enrollment in Study to Assess Nemolizumab in Adults With Chronic Pruritus of Unknown Origin
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the first patient enrollment for its phase II study investigating the efficacy and safety of ...
08.12.25 - dpa-AFX
Galderma erhält mit L'Oréal einen neuen Hauptaktionär
Der Kosmetikkonzern L'Oreal verstärkt sein Engagement beim Schweizer Dermatologiespezialisten Galderma . Die Franzosen wollen 10 Prozent der Galderma-​Anteile von den ...
08.12.25 - Businesswire
Galderma Welcomes Increased Equity Investment From L’Oréal
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring ...
05.12.25 - Businesswire
Galderma Opens up New Chapter for Sculptra® with MDR Certification and New Expanded Indication for Body
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the certification of Sculptra for body indications in the European Union (EU) following its ...
04.12.25 - Businesswire
Galderma Secures ‘BBB’ Credit Rating With Positive Outlook from S&P Global Ratings
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that S&P Global Ratings (S&P) has assigned the company a ‘BBB’ long-term issuer ...
17.11.25 - Businesswire
ASDS 2025: Compelling New Data on Restylane, Sculptra and Relfydess Highlight Galderma’s Innovative Injectable Aesthetics Portfolio and Pipeline
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it presented new data from its Injectable Aesthetics portfolio and pipeline at the American ...
14.11.25 - Businesswire
Galderma Completes Successful Placement of CHF 175 Million Bond
NOT FOR DISTRIBUTION IN THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE RESTRICTED BY APPLICABLE LAW OR ...
17.03.25 - PR Newswire
Galderma's Differin is helping destigmatize acne care with first in category Roblox experience
Galderma's Differin is helping destigmatize acne care with first in category Roblox experience PR Newswire

Newssuche

Videos

newspaper
03.02.26
2026 02 03 17 34 Trendjumper Einführung
Zunächst inormieren wir unsere Stammkunden bezüglich des bevorstehenden Seminars und bieten für ... Mehr »